Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group
The incidence of COVID-19 infection was higher in AHSCT-SSc compared to non-AHSCT SSc patients, with no difference in vaccine acceptance rate. COVID-19 vaccination in AHSCT highly fragile patients appeared to provide substantial COVID-19 protection, as shown by their favourable clinical evolution and effective humoral response.
Authors
- Christine Le Maignan
- L. Biard
- D. Farge
- Pauline Lansiaux
- Fanny Urbain (ORCID: https://orcid.org/0000-0002-4942-8660)
- I. Munia
- G. Pugnet
- Benjamin Crichi
- Pedro Henrique Prata
- Carlotta Cacciatore
Institutions
- Université Paris Cité (FR)
- Saint Louis University Hospital (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de Référence des Maladies Autoinflammatoires et des Amyloses (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Hôpital Rangueil (FR)
- Centre d'Immunologie et des Maladies Infectieuses (FR)
- Hôpital Saint-Louis (FR)
- Bicêtre Hospital (FR)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.55563/clinexprheumatol/8o94lv
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00